Sponsor content

Enzyme engineering for rare disease and cancer

Aeglea Biotherapeutics is engineering human enzymes as replacement therapies for the treatment of both inborn errors of metabolism and cancer. To download the full article, please sign in.

1
0
Upvote 1 Comment
Page of
Go to the profile of Aeglea Biotherapeutics

Aeglea Biotherapeutics

Aeglea BioTherapeutics was founded in December 2013 to develop engineered human enzymes invented in the laboratory of George Georgiou, Ph.D. of The University of Texas at Austin. The convergence of discovery and technology has created a significant opportunity for Aeglea to potentially impact both the treatment of inborn errors of metabolism and cancer.

No comments yet.